<DOC>
	<DOCNO>NCT00321919</DOCNO>
	<brief_summary>This study evaluate whether anemia prevention NeoRecormon additional impact reduce cardiovascular risk conventional anemia treatment patient mostly stage IV chronic kidney disease renal anemia . The anticipated time study treatment 2+ year target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Treatment With NeoRecormon ( Epoetin Beta ) Patients With Chronic Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient &gt; =18 year age ; chronic renal anemia ; receive renal replacement therapy . woman pregnant lactating ; previous treatment erythropoietin erythropoietic substance ; blood transfusion within last 3 month ; need dialysis expect next 6 month ; administration another investigational drug within 30 day precede study start , study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>